背景:先前的日本多发性硬化症(MS)和视神经脊髓炎谱系障碍(NMOSD)临床实践指南于2017年发布。最近,六年来的第一次,MS和NMOSD指南制定委员会修订了日本MS指南,NMOSD,和髓鞘少突胶质细胞糖蛋白抗体相关疾病(MOGAD)。
方法:委员会利用建议评估的分级,发展,和评估系统基于“2020年临床实践指南制定手册”。3.0“,重点是临床问题(CQs)。委员会还讨论了CQ以外的临床问题,将它们归类为问答(Q&A)部分,包括“专家意见在一定程度上同意的问题”和“重要但未包含在CQ中的问题”。
结果:委员会确定了与MS相关的3、1和1个关键CQ,NMOSD,和MOGAD,分别,并提出了建议。关于MS的疾病改善疗法和复发预防疗法的问答环节,NMOSD,和MOGAD进行。修订后的指南于2023年9月发布。
结论:日本MS临床实践指南,NMOSD,和MOGAD更新。MS的治疗策略,NMOSD,和MOGAD正在改变,这些更新的指南可能有助于临床实践中这些疾病的治疗决策。
BACKGROUND: The previous Japanese clinical practice
guidelines for multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) were published in 2017. Recently, for the first time in 6 years, the MS and NMOSD
guideline development committee revised the Japanese
guidelines for MS, NMOSD, and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).
METHODS: The committee utilized the Grading of Recommendations Assessment, Development, and Evaluation system based on the \"Minds Handbook for Clinical Practice
Guideline Development 2020 Ver. 3.0″ with a focus on clinical questions (CQs). The committee also discussed clinical issues other than CQs, categorizing them as a question-and-answer (Q&A) section, including \"issues on which experts\' opinions agree to a certain extent\" and \"issues that are important but not included in the CQ\".
RESULTS: The committee identified 3, 1, and 1 key CQs related to MS, NMOSD, and MOGAD, respectively, and presented recommendations. A Q&A session regarding disease-modifying therapies and relapse prevention therapies for MS, NMOSD, and MOGAD was conducted. The revised
guidelines were published in September 2023.
CONCLUSIONS: The Japanese guidelines for clinical practice on MS, NMOSD, and MOGAD were updated. Treatment strategies for MS, NMOSD, and MOGAD are changing, and these updated guidelines may assist with treatment decisions for these diseases in clinical practice.